Avacta’s FAP-Dox Shows Promising Phase 1 Results in Cancer Treatment

Avacta Group plc ( (GB:AVCT) ) has issued an announcement.

Avacta Therapeutics presented promising Phase 1 data for its lead candidate, FAP-Dox (AVA6000), at the 2025 AACR Annual Meeting. The data showed significant efficacy in treating salivary gland cancers with a high disease control rate and no severe cardiac toxicity, highlighting the potential of Avacta’s tumor-targeted approach. The results suggest a substantial improvement over conventional chemotherapy, with a favorable safety profile and extended progression-free survival, underscoring the potential of Avacta’s pipeline to deliver meaningful patient benefits and drive stakeholder value.

More about Avacta Group plc

Avacta Therapeutics is a clinical-stage life sciences company focused on developing next-generation peptide drug conjugates (PDC) through its proprietary pre|CISION® platform. This platform targets fibroblast activation protein-alpha (FAPα) to deliver potent anti-tumor therapies directly to tumors, minimizing systemic toxicity and enhancing efficacy.

YTD Price Performance: -37.00%

Average Trading Volume: 1,861,978

Technical Sentiment Signal: Buy

Current Market Cap: £120.8M

See more data about AVCT stock on TipRanks’ Stock Analysis page.